Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
McKesson
Boehringer Ingelheim
AstraZeneca
Baxter

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR BGB-290


✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for BGB-290

Trial ID Title Status Sponsor Phase Summary
NCT02343120 ↗ Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Completed BeiGene Phase 1/Phase 2 This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-3111 in patients with B-Cell Lymphoid Malignancies.
NCT02361723 ↗ Phase 1a/1b BGB-290 for Advanced Solid Tumors. Completed BeiGene Phase 1 The study contains Phase 1A and Phase 1B. Phase 1A has Part1 (BID Dose Escalation) and Part2 (QD Dosing Escalation) Evaluation of a cohort of at least three participants completing one cycle of treatment at that dose level and dose regimen is required prior to determining the next dose level and dose regimen for the next cohort. Phase 1B has PartA (BID Dosing Expansion) will investigate efficacy in participants with selected tumor types and further evaluate safety and tolerability of BGB 290 at recommended dose for future studies. and PartB (Food Effect) will investigate the food effect on the Pharmacokinetics (PK) of BGB 290 in participants with advanced solid tumors.
NCT02569476 ↗ BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies Completed BeiGene Phase 1 This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.
NCT02610361 ↗ Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors Completed BeiGene Phase 1 This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.
NCT02660034 ↗ The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed Myriad Genetic Laboratories, Inc. Phase 1 The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Participants With Advanced Solid Tumors
NCT02660034 ↗ The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed BeiGene Phase 1 The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Participants With Advanced Solid Tumors
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for BGB-290

Condition Name

Condition Name for
Intervention Trials
Non-small Cell Lung Cancer 5
Marginal Zone Lymphoma 5
Healthy Volunteers 4
Small Lymphocytic Lymphoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Neoplasms 25
Lymphoma 23
Carcinoma 12
Lung Neoplasms 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for BGB-290

Trials by Country

Trials by Country for
Location Trials
China 536
United States 296
Australia 131
France 71
Japan 70
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Texas 24
California 19
Tennessee 17
New York 17
Pennsylvania 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for BGB-290

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 21
Phase 2 39
Phase 1/Phase 2 14
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 38
Completed 29
Active, not recruiting 17
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BGB-290

Sponsor Name

Sponsor Name for
Sponsor Trials
BeiGene 87
BeiGene USA, Inc. 3
National Cancer Institute (NCI) 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 98
Other 24
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Colorcon
Medtronic
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.